---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-028128"
form_type: "8-K"
ticker: "SGMO"
cik: "0001001233"
company_name: "SANGAMO THERAPEUTICS, INC"
filed_at: "2026-04-29T23:59:59+00:00"
generated_at: "2026-05-15T01:35:23.318889+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sangamo Therapeutics receives Nasdaq delisting notice; trading to be suspended May 5, 2026

## Summary
- Nasdaq staff determined to delist SGMO due to failure to meet minimum bid price requirement.
- Trading will be suspended at open on May 5, 2026; company plans to appeal before Nasdaq Hearings Panel.
- Common stock approved for quotation on OTCQB Venture Market starting May 5, 2026 under symbol SGMO.
- Company previously received two compliance periods but remained non-compliant with bid price rule.

## SEC filing metadata
- accession: 0001628280-26-028128
- form_type: 8-K
- ticker: SGMO
- cik: 0001001233
- company_name: SANGAMO THERAPEUTICS, INC
- filed_at: 2026-04-29T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001233/000162828026028128/0001628280-26-028128-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001233/000162828026028128/sgmo-20260428.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-028128
- JSON: https://secwatch.observer/filing/0001628280-26-028128.json
- Plain text: https://secwatch.observer/filing/0001628280-26-028128.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.